Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / MRNA

Stock rating · Biological Products, (No Diagnostic Substances)

Moderna, Inc. (MRNA) Stock Rating & Analysis

As of November 20, 2026, MELANY rates Moderna, Inc. 53 out of 100 (Promising). Its highest factor score is earnings track record at 100, and its lowest is business quality at 29.

MELANY ratingRated 2026-11-20

MRNA · composite score

53/100
Promising
Nov 20
Rating date
Live price in the app →
Quality29
Momentum66
Risk-adjusted65
Source basis SEC filings and live market dataDated snapshot

About Moderna, Inc.

Moderna is a commercial-stage biotech founded in 2010 that went public in December 2018. Its mRNA technology was validated by its covid vaccine, authorized in the US in December 2020. As of August 2025 the company had 35 mRNA candidates in clinical studies, spanning infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Rating as of 2026-11-20 · this is a dated snapshot; the live rating and the live price are in the app (the rating is part of Pro, free for 30 days).

Why MRNA scores 53/100

MRNA's 8 factor scores run from 29 to 100, and 3 of them sit above its composite of 53. Here is how MRNA breaks down.

Valuation33/100

Whether the price looks cheap or expensive against earnings, growth, and peers.

Business quality29/100

Margins, returns on capital, and balance-sheet strength.

Price momentum66/100

Direction and relative strength of the recent share-price trend.

  • 50-day MA above 200-day (golden cross zone)
Earnings track record100/100

History of beating or missing estimates, and where estimates are heading.

  • Beat EPS estimates 4 of last 4 quarters
  • Avg EPS beat +44%
Analyst sentiment39/100

What Wall Street price targets and revisions are signalling.

Catalyst setup47/100

Near-term events that could move the stock.

Risk-adjusted profile65/100

Upside weighed against volatility and drawdown risk.

Macro fit50/100

How the current rate and market regime suits this kind of company.

How MRNA compares

As of November 20, 2026, Moderna, Inc. is tied for 13th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 55.

All stock rating pages.

Key risks for MRNA

  • Operating margin -116%, currently unprofitable on a trailing basis
  • Negative free cash flow, company consuming cash, not generating it
  • Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt
  • No positive trailing earnings, valuation cannot be anchored to current P/E

Sector and theme context

Moderna, Inc. sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 97/100 for strength. Theme strength feeds MRNA's momentum and catalyst factors above.

MRNA trade plan (Pro)

MELANY has a full position plan for Moderna, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.

Suggested entry zoneLocked
Alert levelLocked
Position sizingLocked
Review triggersLocked

How MELANY rates MRNA

MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Moderna, Inc.'s 53/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.

Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.

Frequently asked questions about MRNA

Is Moderna, Inc. (MRNA) a buy?

As of 2026-11-20, MELANY rated Moderna, Inc. Promising with a composite score of 53/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.

How does MRNA rank against similar companies?

As of November 20, 2026, Moderna, Inc. is tied for 13th of 20 in MELANY's GLP-1, Obesity and Biotech Stocks list, where the average score is 55. Among the other names in the list, the highest scores belong to REGN (74) and LLY (68).

Should I buy Moderna, Inc. stock?

That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Moderna, Inc. (MRNA) Promising with a composite of 53/100 as of 2026-11-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.

What is the MRNA stock price forecast?

MELANY does not publish price targets or forecasts for MRNA. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 53/100 across eight factors for Moderna, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive. What it does read for MRNA as of 2026-11-20: its analyst sentiment factor is 39/100, and its price momentum factor is 66/100.

Is MRNA stock overvalued or undervalued?

MELANY's valuation factor currently reads 33/100 for Moderna, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives MRNA's read.

What price should I buy MRNA at?

Rather than chasing the current price, MELANY computes a smart entry zone for MRNA: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.

What are the risks of buying MRNA stock?

The top risks MELANY currently flags for Moderna, Inc.: Operating margin -116%, currently unprofitable on a trailing basis; Negative free cash flow, company consuming cash, not generating it; Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.

Is Moderna, Inc. a good long-term investment?

For long-term durability the two factors that matter most are business quality, which MELANY scores 29/100 for Moderna, Inc., and earnings track record, at 100/100. The 53/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.

Will MRNA stock go up?

Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 66/100 for MRNA right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.

How current is this MRNA rating?

The rating on this page is a snapshot of MELANY's read as of 2026-11-20, and the score is not recomputed on this page. MELANY re-scores MRNA as new price, earnings, and fundamental data arrive; the current rating and the live price are in the app (the rating is part of Pro, free for 30 days).

How this rating works

Market Eyes Live

Every rating graded in public, MRNA included

MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.

Get the free iOS app Create a free account on the web Free account, no card. Pro: 30 days free, then $9.99 a month.